BOLT — Bolt Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $13.55m
- -$33.77m
- $7.69m
- 22
- 57
- 14
- 21
Annual income statement for Bolt Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.231 | 1.26 | 5.73 | 7.88 | 7.69 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 49.4 | 94 | 96 | 84.1 | 76.1 |
| Operating Profit | -49.2 | -92.8 | -90.3 | -76.2 | -68.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -60.7 | -98.6 | -88.1 | -69.2 | -63.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -60.7 | -98.6 | -88.1 | -69.2 | -63.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -60.7 | -98.6 | -88.1 | -69.2 | -63.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -60.7 | -98.6 | -88.1 | -69.2 | -63.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.67 | -2.64 | -2.36 | -1.83 | -1.65 |